BC Platforms, Negen Partner on Early Disease Risk Assessment Tool

August 8, 2018
BC Platforms, Negen Partner on Early Disease Risk Assessment Tool
Finnish genetic testing and analyzing technology company Negen will use BC Platforms' genomic data management platform (pictured) toward the early risk assessment of common diseases. [Source: BC Platforms]

BC Platforms said today its genomic data management platform will be used by the Finnish genetic testing and analyzing technology company Negen toward the early risk assessment of common diseases, through an agreement whose value was not disclosed.

The companies plan to develop a combined solution for healthcare providers and customers globally, through which BC Platforms’ genomic data management platform would be integrated with Negen’s Genetic Risk Scoring tools.

By incorporating a patient's genetic information as a part of their process of predicting clinical disease risk, the companies say, clinical practitioners can have greater confidence of offering more accurate treatment recommendations to patients, thus lowering costs for healthcare providers.

“With the increased adoption of precision medicine, we are noticing that more of our customers are demanding the ability to populations-based precision medicine initiatives that require access to credible genetic risk scoring tools,” BC Platforms CEO Tero Silvola said in a statement. “We are pleased to partner with Negen to add this downstream capability to our platform.”

Founded in 1997 as a spinout of the Whitehead Institute for Biomedical Research, BC Platforms is headquartered in Basel, Switzerland, with R&D operations in Helsinki, Finland, and sales and marketing offices in London, Boston, and Vancouver.

“This partnership will greatly increase the awareness and utility of our Genetic Risk Scoring tools and our automatized genetic data interpretation. We look forward to bringing the benefits to both clinicians and patients,” added Negen CEO Kimmo Aro.

With operations in Helsinki and Turku, Finland, Negen provides tools and technology designed to assess individual predisposition for common chronic diseases, such as type 2 diabetes and coronary heart disease, using automatized process algorithms. The technology combines genetic profiling combined with commonly known measurable risk factors, with results published in a genetic interpretation report designed to be easily understood.

Negen’s most comprehensive genetic analysis offering is Negen 360, a €349 ($405) analysis package with gene tests for type 2 diabetes, coronary heart disease (CHD), lipids, blood pressure, predisposition to overweight or obesity, and genetic carrier state of rare diseases.